Acta Med. 2011, 54: 59-62

https://doi.org/10.14712/18059694.2016.19

Serum Level of a Soluble Form of Endoglin (CD105) is Decreased after Goeckerman’s Therapy of Psoriasis

David Pohla, Ctirad Andrýsa, Lenka Borskáb, Zdeněk Fialac, Květoslava Hamákovád, Karel Ettlerd, Jan Krejseka

aCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Clinical Immunology and Allergy, Czech Republic
bCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Pathological Physiology, Czech Republic
cCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Hygiene and Preventive Medicine, Czech Republic
dCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Dermatology and Venereology, Czech Republic

Received July 8, 2010
Accepted January 18, 2011

References

1. Andrys C, Borska L, Pohl D, et al. Goeckerman’s therapy for psoriasis with special reference to serum pentraxin 3 level. Int J Dermatol 2008;47:1011–1014.
2. Andrys C, Borska L, Pohl D, Fiala Z, Hamakova K, Krejsek J. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy. Arch Dermatol Res 2007;298:479–483. <https://doi.org/10.1007/s00403-006-0723-8>
3. Arbiser JL, Govindarajan B, Battle TE, et al. Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol 2006;126:1396–1402. <https://doi.org/10.1038/sj.jid.5700276>
4. Borska L, Fiala Z, Krejsek J, et al. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman’s regimen. Pediatr Dermatol 2007;24:607–612. <https://doi.org/10.1111/j.1525-1470.2007.00548.x>
5. Bhushan M, Young HS, Brenchley PEC, et al. Recent advances in cutaneous angiogenesis. Br J Dermatol 2002;147:418–425. <https://doi.org/10.1046/j.1365-2133.2002.05003.x>
6. Bielenberg DR, Bucana CD, Sanchez R, et al. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol 1998;111:864–872. <https://doi.org/10.1046/j.1523-1747.1998.00378.x>
7. De Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatol Ther 2002;17:341–349.
8. Distler JH, Hirth A, Kurowska-Stolarska M, et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;47:149–161.
9. Duff SE, Li Ch, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17:984–992. <https://doi.org/10.1096/fj.02-0634rev>
10. Goeckerman WH. Treatment of psoriasis. Northwest Med 1925;24:229–231.
11. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial proliferation and TGF-beta/ALK1 signal transduction. The EMBO Journal 2004;23: 4018–4028. <https://doi.org/10.1038/sj.emboj.7600386> <PubMed>
12. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487–498. <https://doi.org/10.1067/mjd.2001.117046>
13. Leong TT, Fearon U, Veale DJ. Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep 2005;7:325–329. <https://doi.org/10.1007/s11926-005-0044-5>
14. Li Ch, Guo B, Wilson PB, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer (Pred. Oncol.) 2000;89: 122–126. <https://doi.org/10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M>
15. Li DY, Sorensen LK, Brooke BS, et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534–1537. <https://doi.org/10.1126/science.284.5419.1534>
16. Nielsen HJ, Christensen IJ, Svendsen MN, et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 2002;51:563–567. <https://doi.org/10.1007/PL00012428>
17. Punyadeera C, Thijssen VL, Tchaikovski S, et al. Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium. Mol Hum Reprod 2006;12: 367–375. <https://doi.org/10.1093/molehr/gal027>
18. Rulo HFC, Westphal JR, van de Kerkhof PCM, de Waal RMW, van Vlijmen IMJJ, Ruiter DJ. Expression of endoglin in psoriatic involved and uninvolved skin. J Dermatol Sci 1995;10:103–109. <https://doi.org/10.1016/0923-1811(95)00397-B>
19. Sabat R, Philipp S, Hoflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779–798. <https://doi.org/10.1111/j.1600-0625.2007.00629.x>
20. Smolej L, Andrys C, Maisnar V, et al. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica 2005;48:57–58.
21. Takahshi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001;7:524–532.
22. Ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008;11:79–89. <https://doi.org/10.1007/s10456-008-9101-9>
23. Van de Kerkhof PC, Rulo HF, van Pelt JP, van Vlijmen-Willems IM, De Jong EM. Expression of endoglin in the transition between psoriatic uninvolved and involved skin. Acta Derm Venereol 1998;78:19–21. <https://doi.org/10.1080/00015559850135760>
24. Westphal JR, Willems HW, Schalkwijk CJM, Ruiter DJ, de Waal RMW. A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 1993;100:27–34. <https://doi.org/10.1111/1523-1747.ep12349946>
25. Wipff J, Avouac J, Borderie D, et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Epub ahead of print), 2008.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive